$4.6M R&D Rebates Bolster INmune Bio’s Cash Runway
Event summary
- $4.6M in R&D rebates received from Australia and UK in June-July 2026.
- Rebates exceed Q2 operating cash burn after adjustments.
- Funds support CORDStrom™ regulatory filings planned for 2026-2027.
The big picture
This cash infusion comes as INmune Bio navigates the capital-intensive late-stage development phase of its two lead candidates. The non-dilutive nature of these funds is particularly valuable, allowing the company to preserve equity while advancing toward potential regulatory milestones that could unlock significant valuation inflection points.
What we're watching
- Regulatory Timing
- Whether INmune Bio can maintain its planned regulatory filing schedule for CORDStrom™ in the UK and EU.
- Cash Efficiency
- How effectively the company deploys these non-dilutive funds to extend runway without additional equity raises.
- Clinical Momentum
- The pace at which XPro1595™ advances through its Phase 2b/3 program for Alzheimer’s disease.
Related topics